Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Teva Pharmaceutical Industries (TEVJF) Gross Margin (2016 - 2025)

Historic Gross Margin for Teva Pharmaceutical Industries (TEVJF) over the last 17 years, with Q4 2025 value amounting to 56.38%.

  • Teva Pharmaceutical Industries' Gross Margin rose 62200.0% to 56.38% in Q4 2025 from the same period last year, while for Dec 2025 it was 51.8%, marking a year-over-year increase of 30500.0%. This contributed to the annual value of 51.79% for FY2025, which is 30500.0% up from last year.
  • As of Q4 2025, Teva Pharmaceutical Industries' Gross Margin stood at 56.38%, which was up 62200.0% from 51.43% recorded in Q3 2025.
  • Teva Pharmaceutical Industries' Gross Margin's 5-year high stood at 56.38% during Q4 2025, with a 5-year trough of 43.21% in Q1 2023.
  • Over the past 5 years, Teva Pharmaceutical Industries' median Gross Margin value was 47.99% (recorded in 2021), while the average stood at 48.55%.
  • Its Gross Margin has fluctuated over the past 5 years, first crashed by -44300bps in 2022, then surged by 86100bps in 2023.
  • Over the past 5 years, Teva Pharmaceutical Industries' Gross Margin (Quarter) stood at 50.0% in 2021, then fell by -9bps to 45.57% in 2022, then increased by 19bps to 54.18% in 2023, then dropped by -7bps to 50.15% in 2024, then increased by 12bps to 56.38% in 2025.
  • Its Gross Margin stands at 56.38% for Q4 2025, versus 51.43% for Q3 2025 and 50.34% for Q2 2025.